ID   MYLIP_HUMAN             Reviewed;         445 AA.
AC   Q8WY64; Q5TIA4; Q9BU73; Q9NRL9; Q9UHE7;
DT   09-NOV-2004, integrated into UniProtKB/Swiss-Prot.
DT   20-DEC-2005, sequence version 2.
DT   10-MAY-2017, entry version 144.
DE   RecName: Full=E3 ubiquitin-protein ligase MYLIP;
DE            EC=2.3.2.27;
DE   AltName: Full=Inducible degrader of the LDL-receptor;
DE            Short=Idol;
DE   AltName: Full=Myosin regulatory light chain interacting protein;
DE            Short=MIR;
DE   AltName: Full=RING-type E3 ubiquitin transferase MYLIP {ECO:0000305};
GN   Name=MYLIP; Synonyms=BZF1, IDOL; ORFNames=BM-023, PP5242;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY,
RP   DEVELOPMENTAL STAGE, FUNCTION, INTERACTION WITH MYOSIN REGULATORY
RP   LIGHT CHAIN (MRLC), AND VARIANT SER-342.
RC   TISSUE=Brain;
RX   PubMed=10593918; DOI=10.1074/jbc.274.51.36288;
RA   Olsson P.-A., Korhonen L., Mercer E.A., Lindholm D.;
RT   "MIR is a novel ERM-like protein that interacts with myosin regulatory
RT   light chain and inhibits neurite outgrowth.";
RL   J. Biol. Chem. 274:36288-36292(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT SER-342.
RA   Shi W., Mullersman J.E.;
RL   Submitted (MAY-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   SER-342.
RC   TISSUE=Bone marrow;
RX   PubMed=11042152; DOI=10.1101/gr.140200;
RA   Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G.,
RA   Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W.,
RA   Tao J., Huang Q.-H., Zhou J., Hu G.-X., Gu J., Chen S.-J., Chen Z.;
RT   "Cloning and functional analysis of cDNAs with open reading frames for
RT   300 previously undefined genes expressed in CD34+ hematopoietic
RT   stem/progenitor cells.";
RL   Genome Res. 10:1546-1560(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   SER-342.
RX   PubMed=15498874; DOI=10.1073/pnas.0404089101;
RA   Wan D., Gong Y., Qin W., Zhang P., Li J., Wei L., Zhou X., Li H.,
RA   Qiu X., Zhong F., He L., Yu J., Yao G., Jiang H., Qian L., Yu Y.,
RA   Shu H., Chen X., Xu H., Guo M., Pan Z., Chen Y., Ge C., Yang S.,
RA   Gu J.;
RT   "Large-scale cDNA transfection screening for genes related to cancer
RT   development and progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:15724-15729(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   MUTAGENESIS OF CYS-387, FUNCTION, SUBCELLULAR LOCATION, AND
RP   AUTOUBIQUITINATION.
RX   PubMed=14550572; DOI=10.1016/S0014-5793(03)01010-X;
RA   Bornhauser B.C., Johansson C., Lindholm D.;
RT   "Functional activities and cellular localization of the ezrin,
RT   radixin, moesin (ERM) and RING zinc finger domains in MIR.";
RL   FEBS Lett. 553:195-199(2003).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH TMEM4.
RX   PubMed=12826659; DOI=10.1074/jbc.M306271200;
RA   Bornhauser B.C., Olsson P.-A., Lindholm D.;
RT   "MSAP is a novel MIR-interacting protein that enhances neurite
RT   outgrowth and increases myosin regulatory light chain.";
RL   J. Biol. Chem. 278:35412-35420(2003).
RN   [11]
RP   FUNCTION, INDUCTION, AND MUTAGENESIS OF CYS-387.
RX   PubMed=19520913; DOI=10.1126/science.1168974;
RA   Zelcer N., Hong C., Boyadjian R., Tontonoz P.;
RT   "LXR regulates cholesterol uptake through Idol-dependent
RT   ubiquitination of the LDL receptor.";
RL   Science 325:100-104(2009).
RN   [12]
RP   FUNCTION.
RX   PubMed=20427281; DOI=10.1074/jbc.M110.123729;
RA   Hong C., Duit S., Jalonen P., Out R., Scheer L., Sorrentino V.,
RA   Boyadjian R., Rodenburg K.W., Foley E., Korhonen L., Lindholm D.,
RA   Nimpf J., van Berkel T.J., Tontonoz P., Zelcer N.;
RT   "The E3 ubiquitin ligase IDOL induces the degradation of the low
RT   density lipoprotein receptor family members VLDLR and ApoER2.";
RL   J. Biol. Chem. 285:19720-19726(2010).
RN   [13]
RP   FUNCTION, AUTOUBIQUITINATION, AND MUTAGENESIS OF TYR-265 AND THR-269.
RX   PubMed=22109552; DOI=10.1073/pnas.1111589108;
RA   Calkin A.C., Goult B.T., Zhang L., Fairall L., Hong C., Schwabe J.W.,
RA   Tontonoz P.;
RT   "FERM-dependent E3 ligase recognition is a conserved mechanism for
RT   targeted degradation of lipoprotein receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:20107-20112(2011).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 369-445 IN COMPLEX WITH
RP   UBE2D1, SUBUNIT, ENZYME REGULATION, IRON-BINDING SITES, AND
RP   MUTAGENESIS OF CYS-387; VAL-389 AND LEU-415.
RX   PubMed=21685362; DOI=10.1101/gad.2056211;
RA   Zhang L., Fairall L., Goult B.T., Calkin A.C., Hong C., Millard C.J.,
RA   Tontonoz P., Schwabe J.W.;
RT   "The IDOL-UBE2D complex mediates sterol-dependent degradation of the
RT   LDL receptor.";
RL   Genes Dev. 25:1262-1274(2011).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase that mediates ubiquitination
CC       and subsequent proteasomal degradation of myosin regulatory light
CC       chain (MRLC), LDLR, VLDLR and LRP8. Activity depends on E2 enzymes
CC       of the UBE2D family. Proteasomal degradation of MRLC leads to
CC       inhibit neurite outgrowth in presence of NGF by counteracting the
CC       stabilization of MRLC by saposin-like protein (CNPY2/MSAP) and
CC       reducing CNPY2-stimulated neurite outgrowth. Acts as a sterol-
CC       dependent inhibitor of cellular cholesterol uptake by mediating
CC       ubiquitination and subsequent degradation of LDLR.
CC       {ECO:0000269|PubMed:10593918, ECO:0000269|PubMed:12826659,
CC       ECO:0000269|PubMed:14550572, ECO:0000269|PubMed:19520913,
CC       ECO:0000269|PubMed:20427281, ECO:0000269|PubMed:22109552}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- ENZYME REGULATION: Can bind 1 iron ion per dimer. Iron binding
CC       seems to decrease LDLR degradation activity.
CC       {ECO:0000269|PubMed:21685362}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Homodimer. Interacts with the E2 ubiquitin-conjugating
CC       enzyme, UBE2D1 (via RING-type zinc finger). Interacts with myosin
CC       regulatory light chain (MRLC) and TMEM4.
CC       {ECO:0000269|PubMed:10593918, ECO:0000269|PubMed:12826659,
CC       ECO:0000269|PubMed:21685362}.
CC   -!- INTERACTION:
CC       Q9Y2B0:CNPY2; NbExp=3; IntAct=EBI-6952711, EBI-1054195;
CC       Q8TD10:MIPOL1; NbExp=3; IntAct=EBI-6952711, EBI-2548751;
CC       Q8WWW0:RASSF5; NbExp=3; IntAct=EBI-6952711, EBI-367390;
CC       Q9Y3Q8:TSC22D4; NbExp=3; IntAct=EBI-6952711, EBI-739485;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000305|PubMed:14550572}.
CC       Cell membrane {ECO:0000269|PubMed:14550572}; Peripheral membrane
CC       protein {ECO:0000269|PubMed:14550572}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8WY64-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8WY64-2; Sequence=VSP_011828, VSP_011829;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed.
CC       {ECO:0000269|PubMed:10593918}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in fetal tissues and higher levels
CC       were detected in placenta and fetal lung.
CC       {ECO:0000269|PubMed:10593918}.
CC   -!- INDUCTION: Expression is directly activated by NR1H2 and NR1H3.
CC       Expression is not dependent of the sterol-response element-binding
CC       proteins (SREBPs). Expression is indirectly induced by LDL.
CC       {ECO:0000269|PubMed:19520913}.
CC   -!- DOMAIN: The RING domain mediates ubiquitination and the neurite
CC       outgrowth inhibitory activity.
CC   -!- DOMAIN: The FERM domain binds phospholipids and mediates
CC       lipoprotein receptors recognition at the plasma membrane through
CC       their cytoplasmic tails.
CC   -!- DOMAIN: The RING-type zinc finger mediates the interaction with
CC       UBE2D E2 enzymes.
CC   -!- PTM: Autoubiquitinated. {ECO:0000269|PubMed:14550572,
CC       ECO:0000269|PubMed:22109552}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF187016; AAF18974.1; -; mRNA.
DR   EMBL; AF006003; AAQ13408.1; -; mRNA.
DR   EMBL; AF006004; AAQ13409.1; -; Genomic_DNA.
DR   EMBL; AF212221; AAF87323.1; -; mRNA.
DR   EMBL; AF258586; AAG23789.1; -; mRNA.
DR   EMBL; BT007055; AAP35704.1; -; mRNA.
DR   EMBL; AL021407; CAI19548.1; -; Genomic_DNA.
DR   EMBL; CH471087; EAW55366.1; -; Genomic_DNA.
DR   EMBL; BC002860; AAH02860.1; -; mRNA.
DR   CCDS; CCDS4536.1; -. [Q8WY64-1]
DR   RefSeq; NP_037394.2; NM_013262.3. [Q8WY64-1]
DR   UniGene; Hs.484738; -.
DR   PDB; 2YHN; X-ray; 3.00 A; A/B=369-445.
DR   PDB; 2YHO; X-ray; 2.10 A; A/C/E/G=369-445.
DR   PDBsum; 2YHN; -.
DR   PDBsum; 2YHO; -.
DR   ProteinModelPortal; Q8WY64; -.
DR   SMR; Q8WY64; -.
DR   BioGrid; 118882; 26.
DR   IntAct; Q8WY64; 25.
DR   MINT; MINT-268789; -.
DR   STRING; 9606.ENSP00000349298; -.
DR   iPTMnet; Q8WY64; -.
DR   PhosphoSitePlus; Q8WY64; -.
DR   BioMuta; MYLIP; -.
DR   DMDM; 84028296; -.
DR   PaxDb; Q8WY64; -.
DR   PRIDE; Q8WY64; -.
DR   DNASU; 29116; -.
DR   Ensembl; ENST00000356840; ENSP00000349298; ENSG00000007944. [Q8WY64-1]
DR   GeneID; 29116; -.
DR   KEGG; hsa:29116; -.
DR   UCSC; uc003nbq.4; human. [Q8WY64-1]
DR   CTD; 29116; -.
DR   DisGeNET; 29116; -.
DR   GeneCards; MYLIP; -.
DR   HGNC; HGNC:21155; MYLIP.
DR   MIM; 610082; gene.
DR   neXtProt; NX_Q8WY64; -.
DR   OpenTargets; ENSG00000007944; -.
DR   PharmGKB; PA134942677; -.
DR   eggNOG; ENOG410IG7I; Eukaryota.
DR   eggNOG; ENOG410XRZN; LUCA.
DR   GeneTree; ENSGT00860000133686; -.
DR   HOGENOM; HOG000007353; -.
DR   HOVERGEN; HBG052549; -.
DR   InParanoid; Q8WY64; -.
DR   KO; K10637; -.
DR   OMA; EALLCML; -.
DR   OrthoDB; EOG091G0A4V; -.
DR   PhylomeDB; Q8WY64; -.
DR   TreeFam; TF351936; -.
DR   Reactome; R-HSA-8866427; VLDLR internalisation and degradation.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; MYLIP; human.
DR   GeneWiki; MYLIP; -.
DR   GenomeRNAi; 29116; -.
DR   PRO; PR:Q8WY64; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000007944; -.
DR   CleanEx; HS_MYLIP; -.
DR   ExpressionAtlas; Q8WY64; baseline and differential.
DR   Genevisible; Q8WY64; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0019898; C:extrinsic component of membrane; IEA:InterPro.
DR   GO; GO:0005622; C:intracellular; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0008092; F:cytoskeletal protein binding; IDA:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:MGI.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0042632; P:cholesterol homeostasis; IEA:Ensembl.
DR   GO; GO:0006928; P:movement of cell or subcellular component; IMP:UniProtKB.
DR   GO; GO:0010989; P:negative regulation of low-density lipoprotein particle clearance; IEA:Ensembl.
DR   GO; GO:0007399; P:nervous system development; IMP:UniProtKB.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IEA:Ensembl.
DR   GO; GO:0031648; P:protein destabilization; IEA:Ensembl.
DR   GO; GO:0000209; P:protein polyubiquitination; TAS:Reactome.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IBA:GO_Central.
DR   GO; GO:0032803; P:regulation of low-density lipoprotein particle receptor catabolic process; IEA:Ensembl.
DR   CDD; cd00162; RING; 1.
DR   Gene3D; 1.20.80.10; -; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR019749; Band_41_domain.
DR   InterPro; IPR000798; Ez/rad/moesin-like.
DR   InterPro; IPR014352; FERM/acyl-CoA-bd_prot_3-hlx.
DR   InterPro; IPR019748; FERM_central.
DR   InterPro; IPR000299; FERM_domain.
DR   InterPro; IPR018979; FERM_N.
DR   InterPro; IPR018980; FERM_PH-like_C.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR029071; Ubiquitin-rel_dom.
DR   InterPro; IPR001841; Znf_RING.
DR   Pfam; PF09380; FERM_C; 1.
DR   Pfam; PF00373; FERM_M; 1.
DR   Pfam; PF09379; FERM_N; 1.
DR   PRINTS; PR00935; BAND41.
DR   PRINTS; PR00661; ERMFAMILY.
DR   SMART; SM00295; B41; 1.
DR   SMART; SM01196; FERM_C; 1.
DR   SUPFAM; SSF47031; SSF47031; 1.
DR   SUPFAM; SSF50729; SSF50729; 1.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   PROSITE; PS50057; FERM_3; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Complete proteome;
KW   Cytoplasm; Iron; Membrane; Metal-binding; Polymorphism;
KW   Reference proteome; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1    445       E3 ubiquitin-protein ligase MYLIP.
FT                                /FTId=PRO_0000055972.
FT   DOMAIN        1    279       FERM. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00084}.
FT   ZN_FING     387    422       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   REGION      431    433       Critical for homodimerization.
FT   METAL       360    360       Iron.
FT   METAL       363    363       Iron.
FT   METAL       368    368       Iron.
FT   VAR_SEQ       1    181       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:11042152}.
FT                                /FTId=VSP_011828.
FT   VAR_SEQ     316    445       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:11042152}.
FT                                /FTId=VSP_011829.
FT   VARIANT     342    342       N -> S (in dbSNP:rs9370867).
FT                                {ECO:0000269|PubMed:10593918,
FT                                ECO:0000269|PubMed:11042152,
FT                                ECO:0000269|PubMed:15498874,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_019805.
FT   MUTAGEN     265    265       Y->A: Unable to clear LDLR from the
FT                                plasma membrane.
FT                                {ECO:0000269|PubMed:22109552}.
FT   MUTAGEN     269    269       T->R: Unable to clear LDLR from the
FT                                plasma membrane.
FT                                {ECO:0000269|PubMed:22109552}.
FT   MUTAGEN     387    387       C->A: Abolishes autoubiquitination.
FT                                {ECO:0000269|PubMed:14550572,
FT                                ECO:0000269|PubMed:19520913,
FT                                ECO:0000269|PubMed:21685362}.
FT   MUTAGEN     387    387       C->A: Abolishes ubiquitin ligase
FT                                activity. {ECO:0000269|PubMed:14550572,
FT                                ECO:0000269|PubMed:19520913,
FT                                ECO:0000269|PubMed:21685362}.
FT   MUTAGEN     389    389       V->R: Inhibits LDLR degradation.
FT                                {ECO:0000269|PubMed:21685362}.
FT   MUTAGEN     415    415       L->E: Inhibits LDLR degradation.
FT                                {ECO:0000269|PubMed:21685362}.
FT   CONFLICT    199    199       K -> R (in Ref. 1; AAF18974).
FT                                {ECO:0000305}.
FT   CONFLICT    262    263       SG -> TR (in Ref. 3; AAF87323).
FT                                {ECO:0000305}.
FT   CONFLICT    309    310       KK -> PRN (in Ref. 3; AAF87323).
FT                                {ECO:0000305}.
FT   HELIX       374    384       {ECO:0000244|PDB:2YHO}.
FT   TURN        388    390       {ECO:0000244|PDB:2YHO}.
FT   STRAND      391    394       {ECO:0000244|PDB:2YHO}.
FT   STRAND      397    400       {ECO:0000244|PDB:2YHO}.
FT   HELIX       409    412       {ECO:0000244|PDB:2YHO}.
FT   TURN        419    421       {ECO:0000244|PDB:2YHO}.
FT   STRAND      427    430       {ECO:0000244|PDB:2YHO}.
SQ   SEQUENCE   445 AA;  49910 MW;  342E643B0532B45C CRC64;
     MLCYVTRPDA VLMEVEVEAK ANGEDCLNQV CRRLGIIEVD YFGLQFTGSK GESLWLNLRN
     RISQQMDGLA PYRLKLRVKF FVEPHLILQE QTRHIFFLHI KEALLAGHLL CSPEQAVELS
     ALLAQTKFGD YNQNTAKYNY EELCAKELSS ATLNSIVAKH KELEGTSQAS AEYQVLQIVS
     AMENYGIEWH SVRDSEGQKL LIGVGPEGIS ICKDDFSPIN RIAYPVVQMA TQSGKNVYLT
     VTKESGNSIV LLFKMISTRA ASGLYRAITE THAFYRCDTV TSAVMMQYSR DLKGHLASLF
     LNENINLGKK YVFDIKRTSK EVYDHARRAL YNAGVVDLVS RNNQSPSHSP LKSSESSMNC
     SSCEGLSCQQ TRVLQEKLRK LKEAMLCMVC CEEEINSTFC PCGHTVCCES CAAQLQSCPV
     CRSRVEHVQH VYLPTHTSLL NLTVI
//
